Pacira BioSciences Inc

PCRX

Equity

ISIN US6951271005 / Valor 12338490

NASDAQ (2024-09-18)

USD 14.65+2.13%

Pacira BioSciences Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Pacira BioSciences Inc is a pharmaceutical company that specializes in developing innovative drug delivery technologies for pain management. Their flagship product, ZILRETTA®, is the first and only approved treatment for osteoarthritis knee pain utilizing extended-release microsphere technology. In addition, the company also offers the iovera° system, an FDA-approved handheld cryoanalgesia device that delivers precise doses of cold temperature to targeted nerves, providing immediate pain relief that can last for up to three months. Pacira BioSciences Inc's proprietary multivesicular liposome (pMVL) technology allows for the encapsulation of drugs without altering their molecular structure, ensuring effective and long-lasting pain management solutions for patients.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue

Pacira BioSciences Inc. reported total revenues of $167.1 million for the first quarter of 2024. This represents an increase from the $160.3 million reported in the first quarter of 2023. The revenue growth was driven by strong sales across its product portfolio.

Net Product Sales

In the first quarter of 2024, Pacira BioSciences Inc. achieved net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°. These figures indicate a solid performance for all three of the company's key products.

Net Income

Pacira BioSciences Inc. reported a net income of $9.0 million, or $0.19 per share (basic and diluted), for the first quarter of 2024. This is a significant improvement compared to the GAAP net loss of $19.5 million, or $(0.43) per share, reported in the first quarter of 2023.

Adjusted EBITDA

The company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $44.6 million for the first quarter of 2024. This is an increase from the $41.9 million reported in the first quarter of 2023, reflecting improved operational efficiency.

Financial Guidance

Pacira BioSciences Inc. reiterated its full-year 2024 financial guidance, projecting total revenue between $680 million and $705 million. The company also expects a non-GAAP gross margin of 74% to 76%, non-GAAP R&D expenses of $70 million to $80 million, and non-GAAP SG&A expenses of $245 million to $265 million.

Summarized from source with an LLMView Source

Key figures

-55.6%1Y

-73.8%3Y

-60.6%5Y

Performance

79.6%1Y

54.9%3Y

50.8%5Y

Volatility